Table 1.
Sensitivity of 60 myeloma primary samples to BCL2 and MCL1 inhibitor combination.
| # | Characteristics of patient | % of cell death (MCL1i + BCL2i) | |||
|---|---|---|---|---|---|
| Age/sex | Disease | Status | % of PC | ||
| 1 | 58/F | MM | Diag | 3% | 78 |
| 2 | 70/F | MM | Diag | 19% | 85 |
| 3 | 73/M | MM | Diag | 9% | 88 |
| 4 | 59/M | MM | Diag | 7% | 93 |
| 5 | 70/M | MM | Diag | 12% | 97 |
| 6 | 65/M | MM | Diag | 4% | 99 |
| 7 | 72/M | MM | Rel | 6% | 70 |
| 8 | 62/M | MM | Rel | 13% | 89 |
| 9 | 71/M | MM | Rel | 5% | 92 |
| 10 | 61/F | MM | Rel | 13% | 94 |
| 11 | 45/F | MM | Rel | 4% | 96 |
| 12 | 53/M | MM | Rel | 22% | 97 |
| 13 | 69/M | MM | Rel | 37% | 98 |
| 14 | 69/F | MM | Rel | 4% | 100 |
| 15 | 61/M | MM | Diag | 9% | 84 |
| 16 | 59/M | MM | Diag | 6% | 95 |
| 17 | 74/M | MM | Diag | 20% | 98 |
| 18 | 55/M | MM | Diag | 21% | 99 |
| 19 | 56/M | MM | Diag | 39% | 99 |
| 20 | 76/M | MM | Diag | 18% | 99 |
| 21 | 65/M | MM | Rel | 18% | 57 |
| 22 | 65/F | MM | Rel | 5% | 63 |
| 23 | 58/M | MM | Rel | 4% | 84 |
| 24 | 61/F | MM | Rel | 4% | 89 |
| 25 | 66/F | sPCL | Rel | 12% | 97 |
| 26 | 83/F | MM | Rel | 9% | 97 |
| 27 | 62/F | MM | Rel | 19% | 98 |
| 28 | 60/M | MM | Rel | 8% | 100 |
| 29 | 70/F | MM | Rel | 18% | 100 |
| 30 | 76/M | MM | Diag | 3% | 9 |
| 31 | 88/F | MM | Diag | 4% | 38 |
| 32 | 82/F | MM | Diag | 3% | 41 |
| 33 | 73/F | MM | Diag | 17% | 50 |
| 34 | 55/F | MM | Diag | 8% | 51 |
| 35 | 66/F | MM | Diag | 21% | 53 |
| 36 | 71/F | MM | Diag | 23% | 59 |
| 37 | 56/F | MM | Diag | 22% | 73 |
| 38 | 67/F | MM | Diag | 6% | 82 |
| 39 | 66/M | MM | Diag | 15% | 89 |
| 40 | 54/F | MM | Diag | 43% | 94 |
| 41 | 58/F | sPCL | Rel | 80% | 0 |
| 42 | 60/F | MM | Rel | 10% | 11 |
| 43 | 83/M | MM | Rel | 14% | 12 |
| 44 | 81/F | sPCL | Rel | 22% | 22 |
| 45 | 63/F | MM | Rel | 20% | 33 |
| 46 | 81/M | MM | Rel | 9% | 45 |
| 47 | 72/M | MM | Rel | 26% | 53 |
| 48 | 70/M | MM | Rel | 4% | 56 |
| 49 | 76/M | MM | Rel | 8% | 59 |
| 50 | 78/M | MM | Rel | 11% | 60 |
| 51 | 72/M | MM | Rel | 59% | 66 |
| 52 | 63/F | MM | Rel | 21% | 71 |
| 53 | 70/M | sPCL | Rel | 8% | 71 |
| 54 | 65/M | MM | Rel | 3% | 72 |
| 55 | 78/M | MM | Rel | 4% | 80 |
| 56 | 74/F | MM | Rel | 7% | 80 |
| 57 | 64/M | sPCL | Rel | 31% | 88 |
| 58 | 86/F | MM | Rel | 76% | 88 |
| 59 | 82/M | sPCL | Rel | 23% | 91 |
| 60 | 76/M | MM | Rel | 7% | 99 |
The percentage of cell death induced by the BCL2 and MCL1 inhibitor combination (300 nM of venetoclax with 25 nM of S63845 or 2.5 μM of A1210477) was indicated. Patients have been ordered according to clustering defined in Fig. 2a: patients #1 to #14 were highly BCL2 dependent (red cluster); patients #15 to # 29 were highly MCL1 dependent (blue cluster) and patients #30 to # 60 were resistant or poorly sensitive to MCL1, BCL2, or both inhibitors (green cluster).
F female, M male, MM multiple myeloma, sPCL secondary plasma cell leukemia, Diag diagnosis, Rel relapse, PC plasma cells.